Novel EGFR antibody outperforms cetuximab in mouse model of lung cancer

Armen Hareyan's picture

Lung Cancer Therapy

Antibodies that selectively bind and destroy cancer cells represent some of the most promising cancer therapy approaches being developed today. Several of these antibodies have reached the market, including cetuximab (Erbitux

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.